What is RESTASIS^®

Get more detailed information about RESTASIS^® Ophthalmic Emulsion.

The RESTASIS^®
Smart Start Program

Help your first-time RESTASIS^® patients save money on their prescriptions.

RESTASIS^® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Important Safety Information:

RESTASIS^® is contraindicated in patients with active ocular infections and has not been studied in patients with a history of herpes keratitis.

The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see full prescribing information for RESTASIS^® (cyclosporine ophthalmic emulsion) 0.05%.